ISCHEMIC HEART DISEASE: PATHOGENESIS AND TREATMENTAuthors
Keywords:
Ischemic heart disease, heart muscleAbstract
This monograph provides a comprehensive analysis of the pathogenesis, clinical course, and pharmacotherapeutic approaches to Ischemic heart disease (IHD). IHD, a condition resulting from inadequate blood supply to the heart muscle or complete cessation of blood flow, can lead to conditions such as myocardial infarction, angina, and other cardiovascular disorders. The monograph delves into the molecular and cellular mechanisms involved in the development of IHD, primarily focusing on atherosclerosis and the narrowing of blood vessels. It describes key clinical features, symptoms, diagnostic methods, and the latest treatment strategies. Additionally, the effectiveness of pharmacotherapy approaches, including the role of angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, statins, and thrombolytic agents, is explored in detail.
This work not only presents scientific analysis and theoretical foundations but also offers practical advice for clinical practice. It emphasizes the prevention of IHD, new therapeutic approaches, and the effectiveness of various medications in managing the disease. This monograph serves as a valuable resource for medical professionals, cardiologists, and students, as well as anyone seeking in-depth knowledge about ischemic heart disease.
References
A.Gadayev. Ichki kasalliklar. - Toshkent: “Turon zamin ziyo”, 2016. - 800 b.
Amsterdam E.A., Wenger N.K., Brindis R.G., et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes // Journal of the American College of Cardiology. 2014. Vol. 64, No 24. P. e139-e228.
Braunwald E., Zipes D.P., Libby P., Bonow R.O. Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Philadelphia: Elsevier Saunders, 2013. 2496 p.
Fuster V., Walsh R.A., Harrington R.A. Hurst’s The Heart. 14th ed. New York: McGraw-Hill Education, 2017. 3168 p.
Giannuzzi P., Saner H., Björnstad H., et al. Secondary Prevention Through Cardiac Rehabilitation: Position Paper of the Study Group on Rehabilitation, Exercise, and Implantable Devices of the European Society of Cardiology // European Heart Journal. 2003. Vol. 24, No 13. P. 1273-1278.
Ibanez B., James S., Agewall S., et al. 2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation // European Heart Journal. 2018. Vol. 39, No 2. P. 119-177.
Neumann F.-J., Sousa-Uva M., Ahlsson A., et al. 2018 ESC/EACTS Guidelines on Myocardial Revascularization // European Heart Journal. 2019. Vol. 40, No 2. P. 87-165.
Qosimova N.A. “Yurak ishemik kasalligi bilan bemorlarda koronar arteriyalar shikastlanishi va lipid profil darajasining o‘zaro bog‘liqligi”. Экономика и социум. 5-1(96), 2022.
Smith S.C. Jr., Benjamin E.J., Bonow R.O., et al. AHA/ACC Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update // Journal of the American College of Cardiology. 2011. Vol. 58, No 23. P. 2432-2446.
Smith, J. et al. (2022). Epidemiology of Ischemic Heart Disease. Journal of Cardiology, 78(5), 312-321.
Stone P.H., Raizner A.E., Rihal C.S., et al. Bivalirudin Plus Provisional Glycoprotein IIb/IIIa Inhibitor Versus Heparin Plus Planned Glycoprotein IIb/IIIa Inhibitor During Percutaneous Coronary Intervention: Evaluation of Platelet IIb/IIIa Receptor Inhibition and Benefit // Journal of the American College of Cardiology. 2006. Vol. 47, No 1. P. 65-71.
Wenger N.K., Froelicher E.S., Smith L.K., et al. Cardiac Rehabilitation as Secondary Prevention // Agency for Health Care Policy and Research. Clinical Practice Guidelines, No 96-0672. Rockville, MD: U.S. Department of Health and Human Services, 1995. 300 p.
П. Х. Кардиомиопатии и миокардиты. - М., 2000. - 128 с.
Поздняков Ю.М., Волков В.С. Стенокардия. Москва, 2006.

Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.